Abstract
At its October 2019 meeting, the Advisory Committee on Immunization Practices (ACIP)* voted to recommend approval of the 2020 Recommended U.S. Adult Immunization Schedule for Persons Aged 19 Years and Older. The 2020 adult immunization schedule, available at https://www.cdc.gov/vaccines/schedules/index.html,† summarizes ACIP recommendations in two tables and accompanying notes. This 2020 adult immunization schedule has been approved by the CDC Director, the American College of Physicians, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives. Health care providers are advised to use the tables and the notes together.
Highlights
Advisory Committee on Immunization Practices (ACIP)’s recommendations on use of each vaccine are developed after in-depth reviews of vaccine-related data, including the epidemiology and burden of the vaccine-preventable disease, vaccine efficacy and effectiveness, vaccine safety, quality of evidence, feasibility of program implementation, and economic analyses of immunization policy (1)
Human papillomavirus (HPV) row: The rows for males and females have been combined, reflecting that catch-up vaccination is recommended for all adults aged ≤26 years
Meningococcal B (MenB) row: A blue box has been added for persons aged [19–23] years who are not at increased risk for meningococcal disease, indicating that shared clinical decision-making regarding vaccination is recommended for this group
Summary
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2020. The 2020 adult immunization schedule, available at https://www.cdc.gov/vaccines/ schedules/index.html,† summarizes ACIP recommendations in two tables and accompanying notes. A blue box has been added for persons aged [27–45] years to indicate that shared clinical decision-making regarding vaccination is recommended for this group. Pneumococcal conjugate (PCV13) row: The box for persons aged ≥65 years who do not have an additional risk factor or another indication has been changed to blue to indicate that shared clinical decision-making regarding vaccination is recommended for this group. Meningococcal B (MenB) row: A blue box has been added for persons aged [19–23] years who are not at increased risk for meningococcal disease, indicating that shared clinical decision-making regarding vaccination is recommended for this group.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
